According to Gram Research analysis of 14 studies, vitamin B12 deficiency rates in sickle cell disease vary from 0% to 70% primarily because doctors use different testing methods, not because patients actually have different deficiency rates. Studies using only one B12 test reported mostly 0%-7.1% deficiency, while studies using multiple tests found 6.9%-53%—showing that single tests miss many cases. This diagnostic confusion means patients may be incorrectly diagnosed or missed entirely.
A Gram Research analysis of 14 studies reveals a major problem: doctors are getting wildly different results when testing for vitamin B12 deficiency in sickle cell disease patients, with estimates ranging from 0% to 70%. The issue isn’t that B12 deficiency varies that much between patients—it’s that different testing methods give different answers. Researchers found that most studies used outdated or incomplete testing approaches, making it impossible to know the true rate of B12 deficiency. This matters because patients with sickle cell disease need accurate diagnoses to get the right treatment.
Key Statistics
A 2026 systematic review of 14 studies found that vitamin B12 deficiency prevalence estimates in sickle cell disease ranged from 0% to 70%, with single-marker tests reporting mostly 0%-7.1% and multi-marker tests reporting 6.9%-53%, indicating that testing method—not actual disease prevalence—drives the variation.
According to a 2026 systematic review, 71% of studies examining B12 deficiency in sickle cell disease used immunoassays alone, and over one-third measured only circulating B12 without functional biomarkers, contributing to unreliable and inconsistent diagnostic results.
A 2026 analysis of 14 studies found that diagnostic discordance between different B12 testing methods was substantially greater in lower-income countries (43% of studies) compared to high-income countries (57% of studies), revealing a diagnostic equity problem in sickle cell disease care.
Research reviewed by Gram found that current B12 diagnostic approaches in sickle cell disease are method-dependent rather than reflecting true population differences, with prevalence estimates strongly influenced by whether single or multiple biomarkers were measured.
The Quick Take
- What they studied: Whether the huge differences in B12 deficiency rates reported in sickle cell disease (ranging from 0% to 70%) reflect real differences between patient populations or whether they’re caused by doctors using different testing methods.
- Who participated: Researchers reviewed 14 published studies from 2000 to 2026 that tested B12 levels in sickle cell disease patients. About 57% of studies came from wealthy countries and 43% from lower-income countries.
- Key finding: The wide range of B12 deficiency estimates (0%-70%) is primarily driven by which testing method doctors used, not by actual differences in how many patients have the deficiency. Studies using multiple tests found 6.9%-53% deficiency rates, while studies using single tests found mostly 0%-7.1% (with some outliers at 50%-70%).
- What it means for you: If you have sickle cell disease and get tested for B12 deficiency, the result may depend more on which test your doctor uses than on your actual B12 status. This suggests patients may be misdiagnosed or missed entirely. Ask your doctor which specific B12 tests they’re using and consider getting a second opinion if results seem unclear.
The Research Details
Researchers conducted a systematic review, which means they searched medical databases for all published studies about B12 deficiency in sickle cell disease patients from 2000 through May 2026. They found 14 studies that met their quality standards and analyzed how each one tested for B12 deficiency.
They looked at four key factors that could explain why results differed so much: (1) the type of test used (immunoassay versus other methods), (2) which B12 markers were measured (some tests only checked one marker, others checked multiple), (3) the cutoff values used to define “deficiency,” and (4) whether researchers controlled for other factors that might affect B12 levels.
The researchers created a framework to rate how reliable each study’s diagnostic approach was, considering whether the testing method was appropriate for sickle cell disease patients specifically.
Sickle cell disease is a serious blood disorder that affects how red blood cells function. B12 deficiency can make symptoms worse, so accurate diagnosis is critical. However, sickle cell disease itself can affect B12 test results, making standard tests unreliable. This study matters because it shows that current testing practices don’t account for these complications, leading to confusion about how common B12 deficiency actually is in this population.
This is a high-quality systematic review that followed international standards (PRISMA 2020 guidelines) and was registered before completion. The researchers used multiple databases and checked citations to find studies. However, the underlying studies they reviewed had significant limitations: most used outdated testing methods, didn’t measure all relevant B12 markers, and didn’t account for factors specific to sickle cell disease. The review is only as strong as the studies it analyzed.
What the Results Show
The analysis revealed a striking pattern: when researchers looked at studies using only a single B12 test, prevalence estimates clustered mostly between 0% and 7.1%, but some outliers reported 50%-70%. In contrast, studies using multiple B12 markers reported a wider range of 6.9% to 53%. This dramatic difference suggests that single-marker tests miss many cases of B12 deficiency, while multi-marker approaches catch more.
The researchers found that 71% of studies relied on immunoassays (a common but potentially problematic test for sickle cell patients), and over one-third measured only circulating B12 without checking functional markers that better reflect whether cells can actually use B12. Functional markers—which measure B12’s actual biological activity—are more reliable but were rarely used.
Another key finding: the problem was worse in lower-income countries. Studies from these regions showed greater disagreement between different testing methods, suggesting limited access to comprehensive diagnostic tools. This creates a diagnostic equity problem where patients in lower-income settings may be more likely to receive inaccurate results.
The review found that most studies didn’t adjust for factors that could affect B12 levels in sickle cell disease patients, such as hemolysis (the breakdown of red blood cells), chronic inflammation, or medications. These factors are particularly important in sickle cell disease because the disease itself affects how B12 is processed and used. Without controlling for these factors, test results become even less reliable.
This is the first systematic review to specifically examine why B12 deficiency estimates vary so dramatically in sickle cell disease. Previous research reported prevalence rates anywhere from 0% to 70%, but researchers assumed these differences reflected real variations between patient populations. This study shows that’s not the case—the variation is methodological, not biological. This finding challenges decades of assumptions about B12 deficiency in sickle cell disease.
The review is limited by the quality of available studies. Many studies were small, used outdated methods, or didn’t report enough detail about their testing approach. The researchers couldn’t combine results statistically because the studies were too different from each other. Additionally, the review doesn’t tell us what the true prevalence of B12 deficiency actually is—only that current methods can’t reliably measure it. Finally, some regions had very few studies, making it hard to assess whether geographic differences are real or just reflect which areas have published research.
The Bottom Line
If you have sickle cell disease, ask your doctor to use comprehensive B12 testing that includes both circulating B12 and functional markers (such as methylmalonic acid and homocysteine levels). A single B12 test is likely insufficient. If your initial test shows deficiency, consider getting a second opinion using a different testing method. Healthcare providers should move away from single-marker testing and adopt standardized, multi-marker approaches specifically validated for sickle cell disease patients. Confidence level: High—this recommendation is based on clear evidence that single tests are unreliable.
This research is most important for: (1) people with sickle cell disease who’ve been tested for B12 deficiency, (2) doctors and hematologists treating sickle cell disease, (3) laboratory directors deciding which B12 tests to offer, and (4) researchers studying sickle cell disease. It’s less immediately relevant to people without sickle cell disease, though it highlights broader issues with diagnostic testing standards.
If you’re diagnosed with B12 deficiency and start treatment, you might notice improvements in energy and neurological symptoms within weeks to months. However, the bigger impact of this research is long-term: it will take years for diagnostic standards to change and for new testing protocols to become standard practice in most clinics.
Frequently Asked Questions
How accurate are B12 tests for people with sickle cell disease?
Current B12 tests are unreliable for sickle cell disease patients. A 2026 systematic review found that single-marker tests give very different results than multi-marker tests (0%-7.1% versus 6.9%-53% deficiency rates), suggesting standard tests miss many cases. Ask your doctor to use comprehensive testing with multiple B12 markers.
What’s the difference between single and multi-marker B12 tests?
Single-marker tests measure only circulating B12 levels, which can be misleading in sickle cell disease. Multi-marker tests also measure functional markers like methylmalonic acid and homocysteine, which show whether your cells can actually use B12. Multi-marker testing is more accurate for sickle cell patients.
Why do B12 deficiency rates vary so much in sickle cell disease?
A 2026 review of 14 studies found the variation (0%-70%) is caused by different testing methods, not real differences between patients. Sickle cell disease affects how B12 is processed, making standard tests unreliable. Most studies didn’t account for this, leading to inconsistent results.
Should I get tested for B12 deficiency if I have sickle cell disease?
Yes, but ensure your doctor uses comprehensive testing with multiple B12 markers, not just a single test. A 2026 systematic review showed single tests miss many cases. Ask specifically about methylmalonic acid and homocysteine testing, which are more reliable for sickle cell disease patients.
Is B12 deficiency common in sickle cell disease?
The true prevalence is unknown because testing methods are unreliable. Studies report 0%-70% depending on which test is used. A 2026 systematic review found multi-marker studies reported 6.9%-53%, suggesting deficiency is more common than single-test studies indicated, but the exact rate needs better diagnostic methods.
Want to Apply This Research?
- Track your B12 test results over time, noting the specific test type used (immunoassay, methylmalonic acid, homocysteine, or combination). Record the date, result value, reference range used, and which lab performed the test. This creates a personal record to identify patterns and inconsistencies that might indicate testing problems.
- If you have sickle cell disease, use the app to set a reminder to ask your doctor about comprehensive B12 testing at your next appointment. Document which tests your doctor recommends and request results in writing. If you receive conflicting results from different labs, log both and discuss with your healthcare team.
- Establish a baseline by getting comprehensive B12 testing (multiple markers) at one reliable lab. Then track results annually or as recommended by your doctor. If you change labs or doctors, request that new providers use the same testing method for consistency. Flag any dramatic changes in results between visits for discussion with your care team.
This article summarizes research findings and is not medical advice. B12 deficiency diagnosis and treatment should be managed by qualified healthcare providers familiar with sickle cell disease. Testing methods and treatment recommendations vary by individual and should be discussed with your doctor. If you have sickle cell disease and suspect B12 deficiency, consult a hematologist or your primary care physician before making any changes to your care plan. The findings in this research highlight diagnostic challenges but do not establish definitive prevalence rates or treatment protocols.
This research translation is published by Gram Research, the science division of Gram, an AI-powered nutrition tracking app.